Literature DB >> 22355802

α-Synuclein in Parkinson's disease.

Leonidas Stefanis1.   

Abstract

α-Synuclein is a presynaptic neuronal protein that is linked genetically and neuropathologically to Parkinson's disease (PD). α-Synuclein may contribute to PD pathogenesis in a number of ways, but it is generally thought that its aberrant soluble oligomeric conformations, termed protofibrils, are the toxic species that mediate disruption of cellular homeostasis and neuronal death, through effects on various intracellular targets, including synaptic function. Furthermore, secreted α-synuclein may exert deleterious effects on neighboring cells, including seeding of aggregation, thus possibly contributing to disease propagation. Although the extent to which α-synuclein is involved in all cases of PD is not clear, targeting the toxic functions conferred by this protein when it is dysregulated may lead to novel therapeutic strategies not only in PD, but also in other neurodegenerative conditions, termed synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22355802      PMCID: PMC3281589          DOI: 10.1101/cshperspect.a009399

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  236 in total

1.  Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

Authors:  Takahiko Tokuda; Sultan A Salem; David Allsop; Toshiki Mizuno; Masanori Nakagawa; Mohamed M Qureshi; Joseph J Locascio; Michael G Schlossmacher; Omar M A El-Agnaf
Journal:  Biochem Biophys Res Commun       Date:  2006-08-14       Impact factor: 3.575

2.  Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy.

Authors:  Vinay Choubey; Dzhamilja Safiulina; Annika Vaarmann; Michal Cagalinec; Przemyslaw Wareski; Malle Kuum; Alexander Zharkovsky; Allen Kaasik
Journal:  J Biol Chem       Date:  2011-01-20       Impact factor: 5.157

3.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.

Authors:  N Ostrerova; L Petrucelli; M Farrer; N Mehta; P Choi; J Hardy; B Wolozin
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

4.  Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells.

Authors:  Xiangmin Peng; Xiangmin M Peng; Roya Tehranian; Paula Dietrich; Leonidas Stefanis; Ruth G Perez
Journal:  J Cell Sci       Date:  2005-07-19       Impact factor: 5.285

5.  The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy.

Authors:  Derya R Shimshek; Matthias Mueller; Christoph Wiessner; Tatjana Schweizer; P Herman van der Putten
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

6.  alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis.

Authors:  Maria Xilouri; Tereza Vogiatzi; Kostas Vekrellis; Leonidas Stefanis
Journal:  Autophagy       Date:  2008-10-26       Impact factor: 16.016

7.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

8.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

9.  Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy.

Authors:  Ammar Al-Chalabi; Alexandra Dürr; Nicholas W Wood; Michael H Parkinson; Agnes Camuzat; Jean-Sébastien Hulot; Karen E Morrison; Alan Renton; Sigurd D Sussmuth; Bernhard G Landwehrmeyer; Albert Ludolph; Yves Agid; Alexis Brice; P Nigel Leigh; Gilbert Bensimon
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

10.  Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.

Authors:  Abdelmojib Al-Wandi; Natalia Ninkina; Steven Millership; Sally J M Williamson; Paul A Jones; Vladimir L Buchman
Journal:  Neurobiol Aging       Date:  2008-12-20       Impact factor: 4.673

View more
  344 in total

1.  Applications of iPSC-derived models of Gaucher disease.

Authors:  Daniel K Borger; Elma Aflaki; Ellen Sidransky
Journal:  Ann Transl Med       Date:  2015-11

Review 2.  Autophagy in Alzheimer's disease.

Authors:  Ameneh Zare-Shahabadi; Eliezer Masliah; Gail V W Johnson; Nima Rezaei
Journal:  Rev Neurosci       Date:  2015       Impact factor: 4.353

Review 3.  Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.

Authors:  Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

4.  Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders.

Authors:  André S L M Antunes; Valéria de Almeida; Fernanda Crunfli; Victor C Carregari; Daniel Martins-de-Souza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Membrane insertion exacerbates the α-Synuclein-Cu(II) dopamine oxidase activity: Metallothionein-3 targets and silences all α-synuclein-Cu(II) complexes.

Authors:  Jenifer S Calvo; Neha V Mulpuri; Alex Dao; Nabeeha K Qazi; Gabriele Meloni
Journal:  Free Radic Biol Med       Date:  2020-07-23       Impact factor: 7.376

Review 6.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

7.  Drugena: A Fully Automated Immunoinformatics Platform for the Design of Antibody-Drug Conjugates Against Neurodegenerative Diseases.

Authors:  Louis Papageorgiou; Eleni Papakonstantinou; Constantinos Salis; Eleytheria Polychronidou; Marianna Hagidimitriou; Dimitris Maroulis; Elias Eliopoulos; Dimitrios Vlachakis
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

9.  Untangling alpha synuclein fibrils by graphene quantum dots.

Authors:  Daniel Ysselstein; Dimitri Krainc
Journal:  Mov Disord       Date:  2018-11       Impact factor: 10.338

Review 10.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.